T126322-1mgTAK-901
面议
- 阿拉丁
- 生产商
- T126322-1mg
- 现货
- 全国
规格 |
---|
耗材描述
- 分子式 C28H32N4O3S
- 分子量504.66
属性
溶解性 |
|
存贮条件 | 储存温度-20°C |
描述
备注 | TAK-901 is a novel inhibitor of Aurora A/B with IC50 of 21 nM/15 nM. It is not a potent inhibitor of cellular JAK2, c-Src or Abl. Phase 1. |
生化机理 |
TAK-901 is a small-molecule inhibitor of the serine-threonine kinase Aurora B with potential antineoplastic activity. Aurora B is a positive regulator of mitosis that functions in the attachment of the mitotic spindle to the centromere. This serine/threonine kinase may be amplified and overexpressed by a variety of cancer cell types. After binding of TAK-901 to Aurora B, it inhibits the activity of Aurora B, which may result in a reduction in the proliferation of tumor cells that overexpress Aurora B. TAK-901 is originally developed by Millennium Pharmaceuticals, Inc.. And TAK-901 is been performed phase I clinical trials for the treatment of advanced solid tumors and lymphoma. |
别名 | 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide;5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide |
猜你喜欢
感兴趣产品